Bharat Parenterals Ltd vs Cipla Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Bharat Parenterals Ltd is ₹ 1180 as of 04 May 10:25 . The P/E Ratio of Bharat Parenterals Ltd changed from 9.4 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe P/E Ratio of Cipla Ltd changed from 27.3 on March 2021 to 22.1 on March 2025 . This represents a CAGR of -4.14% over 5 years The Market Cap of Bharat Parenterals Ltd changed from ₹ 192 crore on March 2021 to ₹ 680.55 crore on March 2025 . This represents a CAGR of 28.80% over 5 yearsThe Market Cap of Cipla Ltd changed from ₹ 65746 crore on March 2021 to ₹ 116434 crore on March 2025 . This represents a CAGR of 12.11% over 5 years The revenue of Bharat Parenterals Ltd for the Dec '25 is ₹ 66.52 crore as compare to the Sep '25 revenue of ₹ 68.15 crore. This represent the decline of -2.39% The revenue of Cipla Ltd for the Dec '25 is ₹ 7280 crore as compare to the Sep '25 revenue of ₹ 7858 crore. This represent the decline of -7.35% The ebitda of Bharat Parenterals Ltd for the Dec '25 is ₹ 3.07 crore as compare to the Sep '25 ebitda of ₹ 4.35 crore. This represent the decline of -29.43% The ebitda of Cipla Ltd for the Dec '25 is ₹ 1185 crore as compare to the Sep '25 ebitda of ₹ 2163 crore. This represent the decline of -45.21% The net profit of Bharat Parenterals Ltd changed from ₹ -8.84 crore to ₹ -9.67 crore over 7 quarters. This represents a CAGR of 5.26% The net profit of Cipla Ltd changed from ₹ 1176 crore to ₹ 674.56 crore over 7 quarters. This represents a CAGR of -27.22% The Dividend Payout of Bharat Parenterals Ltd changed from 1.78 % on March 2023 to 2.6 % on March 2025 . This represents a CAGR of 13.46% over 3 yearsThe Dividend Payout of Cipla Ltd changed from 16.34 % on March 2021 to 25.05 % on March 2025 . This represents a CAGR of 8.92% over 5 years .

About Bharat Parenterals Ltd

Bharat Parenterals Limited was incorporated in September, 1992 in Gujarat and promoted by Ramesh Desai and Bharat Desai.
The Company is engaged in the business of manufacturing drugs, pharmaceutical formulations and ayurvedic products at its plant in Baroda.
It has set-up a fully integrated and modern plant as per WHO standards at Haripura near Baroda for manufacturing pharmaceutical formulations, life saving drugs, parenterals and antibiotics. In 2016, Varenyam Healthcare Private Limited was incorporated as wholly owned subsidiary company on 09 July, 2016.
Innoxel Lifesciences was incorporated as wholly owned subsidiary company effective 16th October, 2020.
Varenyam Biolifesciences got incorporated as wholly owned subsidiary company effective from 28th June, 2022.

About Cipla Ltd

Cipla Limited is one of the leading pharmaceutical companies in India.
The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

FAQs for the comparison of Bharat Parenterals Ltd and Cipla Ltd

Which company has a larger market capitalization, Bharat Parenterals Ltd or Cipla Ltd?

Market cap of Bharat Parenterals Ltd is 833 Cr while Market cap of Cipla Ltd is 105,811 Cr

What are the key factors driving the stock performance of Bharat Parenterals Ltd and Cipla Ltd?

The stock performance of Bharat Parenterals Ltd and Cipla Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bharat Parenterals Ltd and Cipla Ltd?

As of May 4, 2026, the Bharat Parenterals Ltd stock price is INR ₹1208.65. On the other hand, Cipla Ltd stock price is INR ₹1309.9.

How do dividend payouts of Bharat Parenterals Ltd and Cipla Ltd compare?

To compare the dividend payouts of Bharat Parenterals Ltd and Cipla Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.